An observational study in Psoriasis, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Al-Azhar University · Observational
Among 54 studies in Psoriasis with a site in Egypt — 16 open to participants now, 16 under way, 2 of them phase 3. Psoriasis · Egypt.
Among the 54 studies in Psoriasis with a site in Egypt, this one is the 5th largest by planned enrollment of the 11 observational ones, is one of 7 that started in 2026, is one of 11 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 47th registered.
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's planned enrollment of 100 is below the median of 199 across 407 observational studies indexed under Psoriasis.
Browse Psoriasis studies →16 of the 54 studies in Psoriasis with a site in Egypt are open now, in 1 country. Each count lists the studies.
Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →54 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2026.
Median enrollment 40 across the 43 interventional studies, 100 across the 11 observational. Of the 27 that completed or were terminated, 2 (7%) have results posted.
3 of 54 have an industry lead sponsor. The 10 most frequent:
Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Al-Azhar University has 3 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
4 of the studies in Psoriasis with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892339Phase 3Cairo UniversityEfficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. | 2026-12-13 |
| NCT07693595Al-Azhar UniversityNailfold Capillaroscopic Changes in Psoriasis | 2026-11-01 |
| NCT07352306Alaa Ashraf Muhammad HelalTopical Diacerein in Psoriasis Vulgaris | 2027-02-01 |
| NCT07713212Cairo UniversityCombined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis | 2027-02-15 |
Among the 54 studies in Psoriasis with a site in Egypt, from their registry updates:
The goal of this observational study is to evaluate nailfold capillaroscopic changes in patients with psoriasis and to assess their correlation with disease severity. The study will also explore differences in capillaroscopic findings across different clinical types of psoriasis and skin phototypes (Fitzpatrick classification). The study will include patients diagnosed with psoriasis attending dermatology outpatient clinics. Participants will undergo clinical assessment and nailfold capillaroscopy to detect microvascular changes.
The study will include patients clinically diagnosed with psoriasis attending the dermatology outpatient clinics at Al-Hussein and Sayed Galal University Hospitals in Cairo, Egypt during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will undergo nailfold capillaroscopy using a USB digital capillaroscope to assess microvascular changes in psoriatic patients. Clinical assessment including PASI score and evaluation of nail involvement will also be performed.
Also known as: Dermoscopy (if used for nails)
Nailfold capillaroscopic abnormalities in psoriasis patients
Detection and description of nailfold capillaroscopic (NFC) abnormalities in patients with psoriasis.
Time frame: Baseline
Variation of nailfold capillaroscopic findings among different clinical types of psoriasis and correlation with disease severity (PASI score).
Correlation between PASI score and presence of NFC changes. \- Comparison of nailfold capillaroscopic findings in different types of psoriasis
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.